Gene · 3452
IFNA21: interferon alpha 21
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. IFNA21: interferon alpha 21. Genes, record 3452. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/3452
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P01568 | Interferon alpha-21 | 189 | 0 | Ensembl, GeneID, HGNC |
Source UniProt
Patents79
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4724500 A2 | 2026-04-15 | 426 | P01568 | Espacenet |
| EP 4705273 A2 | 2026-03-11 | 541 | P01568 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 10286 | P01568 | Espacenet |
| JP 2025169942 A | 2025-11-14 | 1097 | P01568 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 6733 | P01568 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 6652 | P01568 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 6652 | P01568 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 10286 | P01568 | Espacenet |
| JP 2025028160 A | 2025-02-28 | 6733 | P01568 | Espacenet |
| JP 2025013347 A | 2025-01-24 | 541 | P01568 | Espacenet |
1 to 10 of 79
See all 79 patentsDrugs2
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
Trials10
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT01283139 | SIFALIMUMAB | PHASE2 | 2016-07-11 | ClinicalTrials.gov |
| NCT01031836 | SIFALIMUMAB | PHASE2 | 2018-11-19 | ClinicalTrials.gov |
| NCT00979654 | SIFALIMUMAB | PHASE2 | 2016-08-23 | ClinicalTrials.gov |
| NCT00962832 | RONTALIZUMAB | PHASE2 | ClinicalTrials.gov | |
| NCT00657189 | SIFALIMUMAB | PHASE2 | ClinicalTrials.gov | |
| NCT00541749 | RONTALIZUMAB | PHASE1 | ClinicalTrials.gov | |
| NCT00533091 | SIFALIMUMAB | PHASE1 | ClinicalTrials.gov | |
| NCT00482989 | SIFALIMUMAB | PHASE1 | ClinicalTrials.gov | |
| NCT00472758 | SIFALIMUMAB | PHASE1 | ClinicalTrials.gov | |
| NCT00299819 | SIFALIMUMAB | PHASE1 | ClinicalTrials.gov |
NIH grants332
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | IFNA21 papers | Newest fiscal year |
|---|---|---|---|
| UL1TR001866 | Developing, Demonstrating, and Disseminating Innovative Programs to Achieve Translational Success | 5 | 2025 |
| R01AI163029 | Inborn errors of immunity in patients with life-threatening COVID-19 | 3 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 2 | 2025 |
| P51OD010425 | Washington National Primate Research Center | 2 | 2025 |
| UL1TR001863 | Yale Clinical and Translational Science Award | 2 | 2025 |
| ZIAAI000887 | Role of HIV Envelope Proteins In Viral Replication and HIV Pathogenesis | 2 | 2025 |
| I01CX002422 | Investigate the mechanism of autoreactive B cell-mediated immunological failure despite virologic suppression in HIV-infected individuals on antiretroviral therapy | 1 | 2025 |
| K01HL157755 | Tissue-specific functional genomics in the acute respiratory distress syndrome | 1 | 2025 |
| K08AI163493 | Innate Control of Adaptive Immunity to SARS-CoV-2 | 1 | 2025 |
| K24AR076975 | Linking Disease Mechanisms and Outcomes in Rheumatic Diseases | 1 | 2025 |
1 to 10 of 332Source NIH's project files
See all 332 nih grantsPapers292
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Human CD3 complex is required for the generation of T-cell receptor-like chimeric antigen receptor targeting WT1 in natural killer cells. | Cancer Immunol Immunother | 2026 | 41843174 | PubTator, text mining | PubMed |
| Essential role of hsa-miR-203a-3p in type I interferons immune homeostasis during influenza and NDV infection. | RNA Biol | 2026 | 41784292 | PubTator, text mining | PubMed |
| Fetal and Neonatal Immune Response to Congenital Cytomegalovirus (cCMV) Infection: A Systematically Conducted Scoping Review. | Viruses | 2026 | 41754585 | PubTator, text mining | PubMed |
| Somatic deficiency of the human E3 ubiquitin ligase CBL in leukocytes impairs B cell but not T cell development and function. | Nat Immunol | 2026 | 41540267 | PubTator, text mining | PubMed |
| Identification of Transcriptional Regulators of Immune Evasion Across Cancers: An Alternative Immunotherapeutic Strategy for Cholangiocarcinoma. | Cancers (Basel) | 2024 | 39766097 | PubTator, text mining | PubMed |
| Unveiling the therapeutic prospects of IFNW1 and IFNA21: insights into glioma pathogenesis and clinical significance. | Neurogenetics | 2024 | 38958838 | PubTator, text mining | PubMed |
| Inhibition of SARS-CoV-2 infection and replication by Petasites hybridus CO2-extract (Ze 339). | Biomed Pharmacother | 2024 | 38061134 | PubTator, text mining | PubMed |
| A genome-wide and candidate gene association study of preterm birth in Korean pregnant women. | PLoS One | 2023 | 38019868 | PubTator, text mining | PubMed |
| Targeted mutations in IFNα2 improve its antiviral activity against various viruses. | mBio | 2023 | 37874130 | PubTator, text mining | PubMed |
| Rare genetic variants involved in multisystem inflammatory syndrome in children: a multicenter Brazilian cohort study. | Front Cell Infect Microbiol | 2023 | 37588055 | PubTator, text mining | PubMed |
1 to 10 of 292
See all 292 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/3452
GET https://conductscience.org/api/genes/v1/3452/patents?page=2